>
Switch to:

Biomarin Pharmaceutical Long-Term Debt

: $1,078 Mil (As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Biomarin Pharmaceutical's Long-Term Debt for the quarter that ended in Sep. 2021 was $1,078 Mil.

Biomarin Pharmaceutical's quarterly Long-Term Debt increased from Mar. 2021 ($1,076 Mil) to Jun. 2021 ($1,077 Mil) and increased from Jun. 2021 ($1,077 Mil) to Sep. 2021 ($1,078 Mil).

Biomarin Pharmaceutical's annual Long-Term Debt declined from Dec. 2018 ($830 Mil) to Dec. 2019 ($486 Mil) but then increased from Dec. 2019 ($486 Mil) to Dec. 2020 ($1,075 Mil).

Biomarin Pharmaceutical Long-Term Debt Historical Data

The historical data trend for Biomarin Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Long-Term Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 660.76 813.52 830.42 486.24 1,075.15

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Long-Term Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,074.16 1,075.15 1,076.13 1,077.11 1,078.09

Biomarin Pharmaceutical  (NAS:BMRN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biomarin Pharmaceutical Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:ALNY NAS:INCY NAS:ALXN NAS:SRPT NAS:NBIX NAS:BNTX NAS:TECH NAS:MRNA NAS:SGEN NAS:ACAD OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122
Traded in Other Exchanges
BMRN:Mexico 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

From GuruFocus

BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

By PRNewswire 06-25-2021

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

By PRNewswire 07-15-2021

Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $585,060 of Shares

By insider 02-23-2021

Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $657,970 of Shares

By insider 05-13-2021

Biomarin Pharmaceutical Stock Shows Every Sign Of Being Modestly Undervalued

By GF Value 04-29-2021

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

By PRNewswire 03-03-2021

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congres

By PRNewswire 07-19-2021

BioMarin to Participate in Two Upcoming Virtual Investor Conferences

By PRNewswire 05-27-2021

BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstra

By PRNewswire 07-21-2021

Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $676,320 of Shares

By insider 02-19-2021

Other Sources

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

By Zacks 2021-07-21

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

By Zacks 2021-07-28

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

By Zacks 2021-02-26

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

By Zacks 2021-07-23

QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal

By Zacks 2021-07-05

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

By Zacks 2021-07-16

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

By Zacks 2021-07-16

$BMRN - BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript.…

By Seekingalpha 2021-02-26

Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

By Zacks 2021-07-21

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

By Zacks 2021-07-28

BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism

By Zacks 2021-06-28

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates

By Zacks 2021-04-29

$BMRN - BioMarin: One Step Back Before The Jump. Biomarin Pharma One Step Back Before The Jump

By Seekingalpha 2021-03-15

$BMRN - BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead. Biomarin Depressed Price Due To Crl Major Catalysts Ahead

By Seekingalpha 2021-05-31

$BMRN - BioMarin: Too Soon To Buy. Biomarin Too Soon To Buy

By Seekingalpha 2021-06-02

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)